Chronic Obstructive Pulmonary Disease

AstraZeneca in $560 m deal for respiratory firm

British drugmaker AstraZeneca PLC says it is to acquire Pearl Therapeutics Inc., a Redwood-City, California-based company involved in therapies for asthma and chronic obstructive pulmonary disease for at least $560 million.

Jun 10, 2013
popularity not rated yet | comments 0

New factor to control oncogene-induced senescence

An article published on the journal Nature describes the major role that Pyruvate dehydrogenase (PDH) —an enzyme of cellular energy metabolism— plays in the regulation of the cellular senescence induce ...

May 21, 2013
popularity not rated yet | comments 0

Latest Spotlight News

Better living through mitochondrial derived vesicles

(Medical Xpress)—As principal transformers of bacteria, organelles, synapses, and cells, vesicles might be said to be the stuff of life. One need look no further than the rapid rise to prominence of The ...

Biomarker in aggressive breast cancer identified

Two Northwestern University scientists have identified a biomarker strongly associated with basal-like breast cancer, a highly aggressive carcinoma that is resistant to many types of chemotherapy. The biomarker, ...

Common antibiotic linked with heart deaths

The antibiotic clarithromycin—widely used for treating common bacterial infections—is associated with an increased risk of heart deaths, finds a study published in the BMJ today.